New drug targets Hard-to-Treat cancers with KRAS G12D mutation

NCT ID NCT06364696

Ongoing Disease control Sponsor: Astellas Pharma Inc Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 32 times

Summary

This early-stage study tests a new drug called ASP4396 in adults with advanced solid tumors that have a specific change in the KRAS gene (G12D mutation). The main goals are to check safety, find a good dose, and see how the body handles the drug. Participants receive the drug through an IV and are monitored closely for side effects and tumor changes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States
NEXT Oncology Dallas

Irving, Texas, 75039, United States
NEXT Oncology Virginia

Fairfax, Virginia, 22031, United States
START Midwest

Grand Rapids, Michigan, 49546, United States
START Mountain Region

West Valley City, Utah, 84119, United States
University of Kansas Cancer Center

Westwood, Kansas, 66205, United States
University of Rochester

Rochester, New York, 14627, United States

Conditions

Explore the condition pages connected to this study.

SOLID TUMOR